Onxeo adds Dr. Robert Coleman and Dr. Jacques Mallet to its Board as Independent Directors

– FRANCE, Paris –  Onxeo S.A. (EPA: ALONX | Nasdaq: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response in oncology, today announced the appointments of Dr. Robert Coleman and Dr. Jacques Mallet to its Board as Independent Directors.

“We are proud to have such distinguished experts join our Board and to benefit from their rich experience in the healthcare industry.” said Board Chair, Shefali Agarwal.

She added: “Dr. Coleman is an internationally recognized leader in ovarian cancer who strongly contributed to developing many innovative treatments for this highly aggressive form of cancer. Dr. Mallet brings three decades of experience as a strategist and investor in the healthcare business, which is a strong asset for Onxeo’s development. Their complementary background combining outstanding clinical research and management of international pharmaceutical companies makes them an excellent fit for Onxeo as we continue to grow and enhance our research program around AsiDNA™.”

Judith Greciet, CEO said: “I am delighted to welcome these two outstanding experts to our Board. Together with the recent appointment of Shefali Agarwal as our Chairwoman, they will be active support for the Company’s ambitious development program, including its expansion into the United States.”

About Robert L. Coleman, MD

Dr. Robert Coleman is the CSO of US Oncology Network, one of the U.S. largest networks dedicated to advancing high-quality, evidence-based cancer care and research, with more than 400 clinical studies underway and gathering over 1400 physicians. Before joining the US Oncology Network in 2020, Dr. Coleman served as executive director of MD Anderson’s Cancer Network Research Program. Additionally, he was a professor and also served as the Ann Rife Cox Chair in Gynecology at The University of Texas. Dr. Coleman’s work has been featured in over 500 publications focusing on the role of novel therapies in ovarian cancer, such as the incorporation of PARP inhibitors in the treatment strategy.

Dr. Robert Coleman said: “I am very honored to join the Board of Directors of Onxeo. As a cancer specialist, I have dedicated my entire career to improving the way we treat several types of cancer and I’m thrilled to bring my experience to support the development of Onxeo and its pipeline internationally, notably through clinical development in the United States. Based on the extensive dataset collected so far by the team, I believe AsiDNA™ could change cancer treatment paradigm, especially in some selected combinations, and represents a promising way to help patients in need.”

About Jacques Mallet, MD

Dr. Jacques Mallet served as SVP – Head of Portfolio Analytics/Corporate Strategy and Member of the Executive Leadership Team of Sanofi and is currently a board member of several listed or private companies in the health technology sector. He brings to Onxeo more than 30 years of pharmaceutical industry experience within R&D, Pipeline Development, and Corporate Strategy and a unique insight gained in life sciences both in Europe and the United States as a venture capitalist. Before this, Dr. Mallet had been responsible for investments at Auriga Partners, a key life sciences specialized private-equity firm in France, and held some executive positions in global consulting firms such as Monitor Deloitte and Accenture.

Dr. Jacques Mallet commented: “I’m delighted to have the opportunity of joining this strong group of Directors to support the team in the development and growth of the company. I have been impressed by AsiDNA™ and the numerous development opportunities of this potential breakthrough compound. I am now eager to support Onxeo’s highly professional teams to best design the next steps to ensure optimal value creation for the company.”

About Onxeo

Onxeo is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

For more information, visit www.onxeo.com.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.